董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sam Van | 男 | Director | 48 | 1.67万美元 | 未持股 | 2026-06-26 |
| Richard Fang | 男 | Chairman and Director and Interim Chief Executive Officer | 60 | 未披露 | 未持股 | 2026-06-26 |
| George Ye | 男 | Director | 50 | 1.50万美元 | 未持股 | 2026-06-26 |
| Joe Xiao | 男 | Director | 57 | 未披露 | 未持股 | 2026-06-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Matt Schuster | 男 | Chief Operating Officer | 45 | 22.00万美元 | 未持股 | 2026-06-26 |
| Richard Fang | 男 | Chairman and Director and Interim Chief Executive Officer | 60 | 未披露 | 未持股 | 2026-06-26 |
| Georgina Smith | 女 | Chief Accounting Officer | 54 | 未披露 | 未持股 | 2026-06-26 |
| Georgina Smith | 女 | Chief Accounting Officer | 54 | 未披露 | 未持股 | 2026-06-26 |
| Georgina Smith | 女 | Chief Accounting Officer | 54 | 未披露 | 未持股 | 2026-06-26 |
董事简历
中英对照 | 中文 | 英文- Sam Van
-
自本招股说明书发布之日起，Sam Van一直担任我们的董事。Van先生目前担任Deltec Investment Advisers Limited的董事总经理兼负责人，自2018年以来，他一直领导美国和国际交易所上市咨询业务的工作。2019年，范先生受美国政府外国投资委员会CFIUS委托担任联席主席和受托人成员，负责监督投资项目的清算。此前，Van先生于2012年至2017年担任金融业监管局的副负责人，担任过各种职务，包括交易和金融合规检查、销售实践以及金融风险监督和运营监管。在Van于2001年至2011年担任纽约证券交易所董事期间，Van先生负责新业务开发，专门研究整个亚洲的新兴资本市场。范先生在纽约证券交易所获得了60多家公司的担保，总市值超过70亿美元。Van先生获得了圣约翰大学的金融学士学位和康奈尔大学的MBA学位。
Sam Van has served as a member of Picard Medical, Inc.'s Board since September 2025. Sam has been the founder and CEO of SRO Partners since May 2024. He served as the Head of Advisory Services and Senior Vice President for Freedom U.S. Markets, a dividing of Freedom Holding Corp (Nasdaq: FRHC) from September 2022 to May 2024, and as president and a director of Deltec Investment Adviser Limited from May 2017 to September 2022. Earlier in his career, Sam held senior roles at the New York Stock Exchange, including Director of International Listings, where he originated over 60 listings, and as a Senior Examiner in NYSE Regulation. He has also served as a director and as audit committee chair and a member of the nominating committee of Reed's Inc. since October 2024, as a director of Relm Insurance Limited (Bermuda) since January 2019 and as a director for Phoenix Motor, Inc. from June 2022 to May 2024. Sam began his career as an examiner with FINRA. He holds an MBA from Cornell University's Johnson School of Business and a BS in Finance from St. John's University. - 自本招股说明书发布之日起，Sam Van一直担任我们的董事。Van先生目前担任Deltec Investment Advisers Limited的董事总经理兼负责人，自2018年以来，他一直领导美国和国际交易所上市咨询业务的工作。2019年，范先生受美国政府外国投资委员会CFIUS委托担任联席主席和受托人成员，负责监督投资项目的清算。此前，Van先生于2012年至2017年担任金融业监管局的副负责人，担任过各种职务，包括交易和金融合规检查、销售实践以及金融风险监督和运营监管。在Van于2001年至2011年担任纽约证券交易所董事期间，Van先生负责新业务开发，专门研究整个亚洲的新兴资本市场。范先生在纽约证券交易所获得了60多家公司的担保，总市值超过70亿美元。Van先生获得了圣约翰大学的金融学士学位和康奈尔大学的MBA学位。
- Sam Van has served as a member of Picard Medical, Inc.'s Board since September 2025. Sam has been the founder and CEO of SRO Partners since May 2024. He served as the Head of Advisory Services and Senior Vice President for Freedom U.S. Markets, a dividing of Freedom Holding Corp (Nasdaq: FRHC) from September 2022 to May 2024, and as president and a director of Deltec Investment Adviser Limited from May 2017 to September 2022. Earlier in his career, Sam held senior roles at the New York Stock Exchange, including Director of International Listings, where he originated over 60 listings, and as a Senior Examiner in NYSE Regulation. He has also served as a director and as audit committee chair and a member of the nominating committee of Reed's Inc. since October 2024, as a director of Relm Insurance Limited (Bermuda) since January 2019 and as a director for Phoenix Motor, Inc. from June 2022 to May 2024. Sam began his career as an examiner with FINRA. He holds an MBA from Cornell University's Johnson School of Business and a BS in Finance from St. John's University.
- Richard Fang
-
Richard Fang，是投资于医疗器械领域的投资集团Hunniwell Lake Ventures LLC（“HLV”）的创始人和管理合伙人。HLV成立于2019年。HLV最近通过Picard Medical，Inc.收购了SynCardia Systems，后者现已成为HLV公司家族的一部分。除了HLV，Richard于2005年在加州创立了微创手术器械公司Reach Surgical。在15年的时间里，他推动Reach Surgical成长为一个行业领先的品牌，业务遍及六大洲。在此期间，他监督了包括数十个SKU在内的三个产品线的开发、制造、营销和销售。他在Reach Surgical任职期间，在最近将该公司出售给一位私募股权买家的交易中达到了高潮。Richard在医疗器械行业拥有超过20年的专业实践经验，其中包括美国强生。他拥有辛辛那提大学的MBA学位，以及印第安纳波利斯普渡大学的物理学博士学位。作为一名科幻迷，他相信铁人心脏，并有一个愿景，即SynCardia TAH将成为心脏移植的首选替代品。
Richard Fang serves as Picard Medical, Inc.'s Interim Chief Executive Officer, has served as a director since September 2021 and is a founder and managing partner of Hunniwell Lake Ventures LLC ("HLV"), an investment group investing in the medical device space. HLV was formed in 2019. HLV, through Picard Medical, Inc., recently acquired SynCardia Systems, LLC ("SynCardia"), which is now part of the HLV family of companies. In addition to HLV, Richard founded Reach Surgical, a minimally invasive surgical instruments company in California in 2005. Over a 15 year period, he drove the growth of Reach Surgical into an industry leading brand with presence on six continents. During that time, he oversaw the development, manufacturing, marketing, and sales of three product lines including dozens of SKUs. His tenure with Reach Surgical culminated in the recent sale of the company to a private equity buyer. Richard has over 20 years of professional hands on experience in the medical device industry, including Johnson & Johnson in the United States. He has an MBA from the University of Cincinnati, as well as a Ph.D. in Physics from Purdue University in Indianapolis. - Richard Fang，是投资于医疗器械领域的投资集团Hunniwell Lake Ventures LLC（“HLV”）的创始人和管理合伙人。HLV成立于2019年。HLV最近通过Picard Medical，Inc.收购了SynCardia Systems，后者现已成为HLV公司家族的一部分。除了HLV，Richard于2005年在加州创立了微创手术器械公司Reach Surgical。在15年的时间里，他推动Reach Surgical成长为一个行业领先的品牌，业务遍及六大洲。在此期间，他监督了包括数十个SKU在内的三个产品线的开发、制造、营销和销售。他在Reach Surgical任职期间，在最近将该公司出售给一位私募股权买家的交易中达到了高潮。Richard在医疗器械行业拥有超过20年的专业实践经验，其中包括美国强生。他拥有辛辛那提大学的MBA学位，以及印第安纳波利斯普渡大学的物理学博士学位。作为一名科幻迷，他相信铁人心脏，并有一个愿景，即SynCardia TAH将成为心脏移植的首选替代品。
- Richard Fang serves as Picard Medical, Inc.'s Interim Chief Executive Officer, has served as a director since September 2021 and is a founder and managing partner of Hunniwell Lake Ventures LLC ("HLV"), an investment group investing in the medical device space. HLV was formed in 2019. HLV, through Picard Medical, Inc., recently acquired SynCardia Systems, LLC ("SynCardia"), which is now part of the HLV family of companies. In addition to HLV, Richard founded Reach Surgical, a minimally invasive surgical instruments company in California in 2005. Over a 15 year period, he drove the growth of Reach Surgical into an industry leading brand with presence on six continents. During that time, he oversaw the development, manufacturing, marketing, and sales of three product lines including dozens of SKUs. His tenure with Reach Surgical culminated in the recent sale of the company to a private equity buyer. Richard has over 20 years of professional hands on experience in the medical device industry, including Johnson & Johnson in the United States. He has an MBA from the University of Cincinnati, as well as a Ph.D. in Physics from Purdue University in Indianapolis.
- George Ye
-
George Ye，曾在爱德华兹生命科学（NYSE：EW）担任多个职务，包括2019年4月至2024年10月担任大中华区高级副总裁兼总经理，2016年10月至2019年4月担任日本外科副总裁兼总经理，205年4月至2016年9月担任日本和亚太战略高级总监。此前，George曾在雅培和强生担任过多个职务。乔治获得了西北大学化学工程学理学学士学位和MBA学位。
George Ye has served as a member of the Board since September 2025. George previously served in various roles at Edwards Lifesciences (NYSE: EW), including Senior Vice President and General Manager, Greater China Region from April 2019 to October 2024, Vice President and General Manager, Japan Surgical, from October 2016 to April 2019, and Senior Director, Japan and Asia Pacific Strategy from April 2015 to September 2016. Prior, George held various roles at Abbott Laboratories and Johnson & Johnson. George received his Bachelor of Science in Chemical Engineering and his MBA from Northwestern University. - George Ye，曾在爱德华兹生命科学（NYSE：EW）担任多个职务，包括2019年4月至2024年10月担任大中华区高级副总裁兼总经理，2016年10月至2019年4月担任日本外科副总裁兼总经理，205年4月至2016年9月担任日本和亚太战略高级总监。此前，George曾在雅培和强生担任过多个职务。乔治获得了西北大学化学工程学理学学士学位和MBA学位。
- George Ye has served as a member of the Board since September 2025. George previously served in various roles at Edwards Lifesciences (NYSE: EW), including Senior Vice President and General Manager, Greater China Region from April 2019 to October 2024, Vice President and General Manager, Japan Surgical, from October 2016 to April 2019, and Senior Director, Japan and Asia Pacific Strategy from April 2015 to September 2016. Prior, George held various roles at Abbott Laboratories and Johnson & Johnson. George received his Bachelor of Science in Chemical Engineering and his MBA from Northwestern University.
- Joe Xiao
-
Joe Xiao自2026年6月起担任董事会成员。肖博士自2009年7月起担任AnX Robotica和ANKON Technologies的创始人和首席执行官。肖博士是一位连续医疗技术企业家和发明家，拥有50 +项专利，以开创磁控胶囊内窥镜和AI驱动的胃肠诊断而闻名。他在美国和中国建立并扩展了多家全球医疗设备公司，包括ANKON Technologies和AnX Robotica，在成功商业化和战略退出方面有着良好的记录，包括以8000万美元将Argus Medical出售给MicroPort。他于1998年在中佛罗里达大学获得电气工程博士学位。由于具有医疗技术企业家的经验，肖博士有资格担任Picard Medical，Inc.的董事会成员。
Joe Xiao has served as a member of the Board since June 2026. Dr. Xiao has been the founder and CEO of AnX Robotica and ANKON Technologies since July 2009. Dr. Xiao is a serial medtech entrepreneur and inventor with 50+ patents, known for pioneering magnetically controlled capsule endoscopy and AI driven gastrointestinal diagnostics. He has built and scaled multiple global medical device companies across the U.S. and China, including ANKON Technologies and AnX Robotica, with a track record of successful commercialization and strategic exits, including the $80M sale of Argus Medical to MicroPort. He got his Ph.D. in Electric Engineering from University of Central Florida in 1998. - Joe Xiao自2026年6月起担任董事会成员。肖博士自2009年7月起担任AnX Robotica和ANKON Technologies的创始人和首席执行官。肖博士是一位连续医疗技术企业家和发明家，拥有50 +项专利，以开创磁控胶囊内窥镜和AI驱动的胃肠诊断而闻名。他在美国和中国建立并扩展了多家全球医疗设备公司，包括ANKON Technologies和AnX Robotica，在成功商业化和战略退出方面有着良好的记录，包括以8000万美元将Argus Medical出售给MicroPort。他于1998年在中佛罗里达大学获得电气工程博士学位。由于具有医疗技术企业家的经验，肖博士有资格担任Picard Medical，Inc.的董事会成员。
- Joe Xiao has served as a member of the Board since June 2026. Dr. Xiao has been the founder and CEO of AnX Robotica and ANKON Technologies since July 2009. Dr. Xiao is a serial medtech entrepreneur and inventor with 50+ patents, known for pioneering magnetically controlled capsule endoscopy and AI driven gastrointestinal diagnostics. He has built and scaled multiple global medical device companies across the U.S. and China, including ANKON Technologies and AnX Robotica, with a track record of successful commercialization and strategic exits, including the $80M sale of Argus Medical to MicroPort. He got his Ph.D. in Electric Engineering from University of Central Florida in 1998.
高管简历
中英对照 | 中文 | 英文- Matt Schuster
马特·舒斯特，于2023年11月被任命为首席运营官。在担任这一职务之前，Matt在2023年5月至2023年11月期间担任SynCardia的研发总监。从2021年1月到2023年5月，Matt在罗氏担任过多个职务，包括工程承包商、员工机械工程师和系统开发主管。在担任罗氏之前，Matt曾于2018年4月至2021年1月担任SynCardia的制造和设施总监。他在SynCardia的开发项目中发挥了关键作用，包括更小尺寸的50CC全人工心脏和下一代气动驱动器。Matt在北亚利桑那大学获得机械工程学士学位。
Matt Schuster was appointed as Picard Medical, Inc.'s Chief Operating Officer in November 2023. Prior to this role, Matt was the Director of Research and Development for SynCardia from May 2023 to November 2023. From January 2021 through May 2023, Matt held various roles with Roche, including as an Engineering Contractor, Staff Mechanical Engineer, and Systems Development Lead. Prior to his roles at Roche, Matt was the Director of Manufacturing and Facilities at SynCardia from April 2018 to January 2021. He has played a key role in development projects for SynCardia, including the smaller sized 50cc total artificial heart and next generation pneumatic driver. Matt received his Bachelor's degree in Mechanical Engineering from Northern Arizona University.- 马特·舒斯特，于2023年11月被任命为首席运营官。在担任这一职务之前，Matt在2023年5月至2023年11月期间担任SynCardia的研发总监。从2021年1月到2023年5月，Matt在罗氏担任过多个职务，包括工程承包商、员工机械工程师和系统开发主管。在担任罗氏之前，Matt曾于2018年4月至2021年1月担任SynCardia的制造和设施总监。他在SynCardia的开发项目中发挥了关键作用，包括更小尺寸的50CC全人工心脏和下一代气动驱动器。Matt在北亚利桑那大学获得机械工程学士学位。
- Matt Schuster was appointed as Picard Medical, Inc.'s Chief Operating Officer in November 2023. Prior to this role, Matt was the Director of Research and Development for SynCardia from May 2023 to November 2023. From January 2021 through May 2023, Matt held various roles with Roche, including as an Engineering Contractor, Staff Mechanical Engineer, and Systems Development Lead. Prior to his roles at Roche, Matt was the Director of Manufacturing and Facilities at SynCardia from April 2018 to January 2021. He has played a key role in development projects for SynCardia, including the smaller sized 50cc total artificial heart and next generation pneumatic driver. Matt received his Bachelor's degree in Mechanical Engineering from Northern Arizona University.
- Richard Fang
Richard Fang，是投资于医疗器械领域的投资集团Hunniwell Lake Ventures LLC（“HLV”）的创始人和管理合伙人。HLV成立于2019年。HLV最近通过Picard Medical，Inc.收购了SynCardia Systems，后者现已成为HLV公司家族的一部分。除了HLV，Richard于2005年在加州创立了微创手术器械公司Reach Surgical。在15年的时间里，他推动Reach Surgical成长为一个行业领先的品牌，业务遍及六大洲。在此期间，他监督了包括数十个SKU在内的三个产品线的开发、制造、营销和销售。他在Reach Surgical任职期间，在最近将该公司出售给一位私募股权买家的交易中达到了高潮。Richard在医疗器械行业拥有超过20年的专业实践经验，其中包括美国强生。他拥有辛辛那提大学的MBA学位，以及印第安纳波利斯普渡大学的物理学博士学位。作为一名科幻迷，他相信铁人心脏，并有一个愿景，即SynCardia TAH将成为心脏移植的首选替代品。
Richard Fang serves as Picard Medical, Inc.'s Interim Chief Executive Officer, has served as a director since September 2021 and is a founder and managing partner of Hunniwell Lake Ventures LLC ("HLV"), an investment group investing in the medical device space. HLV was formed in 2019. HLV, through Picard Medical, Inc., recently acquired SynCardia Systems, LLC ("SynCardia"), which is now part of the HLV family of companies. In addition to HLV, Richard founded Reach Surgical, a minimally invasive surgical instruments company in California in 2005. Over a 15 year period, he drove the growth of Reach Surgical into an industry leading brand with presence on six continents. During that time, he oversaw the development, manufacturing, marketing, and sales of three product lines including dozens of SKUs. His tenure with Reach Surgical culminated in the recent sale of the company to a private equity buyer. Richard has over 20 years of professional hands on experience in the medical device industry, including Johnson & Johnson in the United States. He has an MBA from the University of Cincinnati, as well as a Ph.D. in Physics from Purdue University in Indianapolis.- Richard Fang，是投资于医疗器械领域的投资集团Hunniwell Lake Ventures LLC（“HLV”）的创始人和管理合伙人。HLV成立于2019年。HLV最近通过Picard Medical，Inc.收购了SynCardia Systems，后者现已成为HLV公司家族的一部分。除了HLV，Richard于2005年在加州创立了微创手术器械公司Reach Surgical。在15年的时间里，他推动Reach Surgical成长为一个行业领先的品牌，业务遍及六大洲。在此期间，他监督了包括数十个SKU在内的三个产品线的开发、制造、营销和销售。他在Reach Surgical任职期间，在最近将该公司出售给一位私募股权买家的交易中达到了高潮。Richard在医疗器械行业拥有超过20年的专业实践经验，其中包括美国强生。他拥有辛辛那提大学的MBA学位，以及印第安纳波利斯普渡大学的物理学博士学位。作为一名科幻迷，他相信铁人心脏，并有一个愿景，即SynCardia TAH将成为心脏移植的首选替代品。
- Richard Fang serves as Picard Medical, Inc.'s Interim Chief Executive Officer, has served as a director since September 2021 and is a founder and managing partner of Hunniwell Lake Ventures LLC ("HLV"), an investment group investing in the medical device space. HLV was formed in 2019. HLV, through Picard Medical, Inc., recently acquired SynCardia Systems, LLC ("SynCardia"), which is now part of the HLV family of companies. In addition to HLV, Richard founded Reach Surgical, a minimally invasive surgical instruments company in California in 2005. Over a 15 year period, he drove the growth of Reach Surgical into an industry leading brand with presence on six continents. During that time, he oversaw the development, manufacturing, marketing, and sales of three product lines including dozens of SKUs. His tenure with Reach Surgical culminated in the recent sale of the company to a private equity buyer. Richard has over 20 years of professional hands on experience in the medical device industry, including Johnson & Johnson in the United States. He has an MBA from the University of Cincinnati, as well as a Ph.D. in Physics from Purdue University in Indianapolis.
- Georgina Smith
Georgina Smith于2026年6月被任命为Picard Medical，Inc.的首席会计官。在被任命之前，Smith女士于2026年1月至2026年5月期间担任SynCardia的财务总监。在加入SynCardia之前，Smith女士于2024年1月至2025年10月担任Rain Bird Corporation的助理公司财务总监，负责企业会计治理、内部控制、财务报告、监管合规和审计准备工作。2014年5月至2023年12月，她在图森电力担任越来越负责任的职务，包括2018年1月至2023年12月的外部报告经理。Smith女士拥有亚利桑那大学工商管理硕士学位和会计学学士学位，是亚利桑那州的注册会计师。
Georgina Smith was appointed as Picard Medical, Inc.'s Chief Accounting Officer in June 2026. Prior to her appointment, Ms. Smith served as Controller of SynCardia from January 2026 to May 2026. Before joining SynCardia, Ms. Smith served as Assistant Corporate Controller of Rain Bird Corporation from January 2024 to October 2025, where she was responsible for enterprise accounting governance, internal controls, financial reporting, regulatory compliance, and audit readiness. From May 2014 to December 2023, she held positions of increasing responsibility at Tucson Electric Power, including Manager of External Reporting from January 2018 to December 2023. Ms. Smith holds a Master of Business Administration and a Bachelor of Science in Accounting from the University of Arizona and is a Certified Public Accountant in the State of Arizona.- Georgina Smith于2026年6月被任命为Picard Medical，Inc.的首席会计官。在被任命之前，Smith女士于2026年1月至2026年5月期间担任SynCardia的财务总监。在加入SynCardia之前，Smith女士于2024年1月至2025年10月担任Rain Bird Corporation的助理公司财务总监，负责企业会计治理、内部控制、财务报告、监管合规和审计准备工作。2014年5月至2023年12月，她在图森电力担任越来越负责任的职务，包括2018年1月至2023年12月的外部报告经理。Smith女士拥有亚利桑那大学工商管理硕士学位和会计学学士学位，是亚利桑那州的注册会计师。
- Georgina Smith was appointed as Picard Medical, Inc.'s Chief Accounting Officer in June 2026. Prior to her appointment, Ms. Smith served as Controller of SynCardia from January 2026 to May 2026. Before joining SynCardia, Ms. Smith served as Assistant Corporate Controller of Rain Bird Corporation from January 2024 to October 2025, where she was responsible for enterprise accounting governance, internal controls, financial reporting, regulatory compliance, and audit readiness. From May 2014 to December 2023, she held positions of increasing responsibility at Tucson Electric Power, including Manager of External Reporting from January 2018 to December 2023. Ms. Smith holds a Master of Business Administration and a Bachelor of Science in Accounting from the University of Arizona and is a Certified Public Accountant in the State of Arizona.
- Georgina Smith
Georgina Smith于2026年6月被任命为Picard Medical，Inc.的首席会计官。在被任命之前，Smith女士于2026年1月至2026年5月期间担任SynCardia的财务总监。在加入SynCardia之前，Smith女士于2024年1月至2025年10月担任Rain Bird Corporation的助理公司财务总监，负责企业会计治理、内部控制、财务报告、监管合规和审计准备工作。2014年5月至2023年12月，她在图森电力担任越来越负责任的职务，包括2018年1月至2023年12月的外部报告经理。Smith女士拥有亚利桑那大学工商管理硕士学位和会计学学士学位，是亚利桑那州的注册会计师。
Georgina Smith was appointed as Picard Medical, Inc.'s Chief Accounting Officer in June 2026. Prior to her appointment, Ms. Smith served as Controller of SynCardia from January 2026 to May 2026. Before joining SynCardia, Ms. Smith served as Assistant Corporate Controller of Rain Bird Corporation from January 2024 to October 2025, where she was responsible for enterprise accounting governance, internal controls, financial reporting, regulatory compliance, and audit readiness. From May 2014 to December 2023, she held positions of increasing responsibility at Tucson Electric Power, including Manager of External Reporting from January 2018 to December 2023. Ms. Smith holds a Master of Business Administration and a Bachelor of Science in Accounting from the University of Arizona and is a Certified Public Accountant in the State of Arizona.- Georgina Smith于2026年6月被任命为Picard Medical，Inc.的首席会计官。在被任命之前，Smith女士于2026年1月至2026年5月期间担任SynCardia的财务总监。在加入SynCardia之前，Smith女士于2024年1月至2025年10月担任Rain Bird Corporation的助理公司财务总监，负责企业会计治理、内部控制、财务报告、监管合规和审计准备工作。2014年5月至2023年12月，她在图森电力担任越来越负责任的职务，包括2018年1月至2023年12月的外部报告经理。Smith女士拥有亚利桑那大学工商管理硕士学位和会计学学士学位，是亚利桑那州的注册会计师。
- Georgina Smith was appointed as Picard Medical, Inc.'s Chief Accounting Officer in June 2026. Prior to her appointment, Ms. Smith served as Controller of SynCardia from January 2026 to May 2026. Before joining SynCardia, Ms. Smith served as Assistant Corporate Controller of Rain Bird Corporation from January 2024 to October 2025, where she was responsible for enterprise accounting governance, internal controls, financial reporting, regulatory compliance, and audit readiness. From May 2014 to December 2023, she held positions of increasing responsibility at Tucson Electric Power, including Manager of External Reporting from January 2018 to December 2023. Ms. Smith holds a Master of Business Administration and a Bachelor of Science in Accounting from the University of Arizona and is a Certified Public Accountant in the State of Arizona.
- Georgina Smith
Georgina Smith于2026年6月被任命为Picard Medical，Inc.的首席会计官。在被任命之前，Smith女士于2026年1月至2026年5月期间担任SynCardia的财务总监。在加入SynCardia之前，Smith女士于2024年1月至2025年10月担任Rain Bird Corporation的助理公司财务总监，负责企业会计治理、内部控制、财务报告、监管合规和审计准备工作。2014年5月至2023年12月，她在图森电力担任越来越负责任的职务，包括2018年1月至2023年12月的外部报告经理。Smith女士拥有亚利桑那大学工商管理硕士学位和会计学学士学位，是亚利桑那州的注册会计师。
Georgina Smith was appointed as Picard Medical, Inc.'s Chief Accounting Officer in June 2026. Prior to her appointment, Ms. Smith served as Controller of SynCardia from January 2026 to May 2026. Before joining SynCardia, Ms. Smith served as Assistant Corporate Controller of Rain Bird Corporation from January 2024 to October 2025, where she was responsible for enterprise accounting governance, internal controls, financial reporting, regulatory compliance, and audit readiness. From May 2014 to December 2023, she held positions of increasing responsibility at Tucson Electric Power, including Manager of External Reporting from January 2018 to December 2023. Ms. Smith holds a Master of Business Administration and a Bachelor of Science in Accounting from the University of Arizona and is a Certified Public Accountant in the State of Arizona.- Georgina Smith于2026年6月被任命为Picard Medical，Inc.的首席会计官。在被任命之前，Smith女士于2026年1月至2026年5月期间担任SynCardia的财务总监。在加入SynCardia之前，Smith女士于2024年1月至2025年10月担任Rain Bird Corporation的助理公司财务总监，负责企业会计治理、内部控制、财务报告、监管合规和审计准备工作。2014年5月至2023年12月，她在图森电力担任越来越负责任的职务，包括2018年1月至2023年12月的外部报告经理。Smith女士拥有亚利桑那大学工商管理硕士学位和会计学学士学位，是亚利桑那州的注册会计师。
- Georgina Smith was appointed as Picard Medical, Inc.'s Chief Accounting Officer in June 2026. Prior to her appointment, Ms. Smith served as Controller of SynCardia from January 2026 to May 2026. Before joining SynCardia, Ms. Smith served as Assistant Corporate Controller of Rain Bird Corporation from January 2024 to October 2025, where she was responsible for enterprise accounting governance, internal controls, financial reporting, regulatory compliance, and audit readiness. From May 2014 to December 2023, she held positions of increasing responsibility at Tucson Electric Power, including Manager of External Reporting from January 2018 to December 2023. Ms. Smith holds a Master of Business Administration and a Bachelor of Science in Accounting from the University of Arizona and is a Certified Public Accountant in the State of Arizona.